| Code | CSB-RA896869MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to the reference antibody described in US10927183B2, specifically targeting VSIG4 (V-Set and Immunoglobulin domain containing 4). VSIG4 is a complement receptor predominantly expressed on tissue-resident macrophages, where it functions as a negative regulator of T cell activation and immune responses. This protein plays a critical role in immune homeostasis by binding complement component C3 and inhibiting T cell proliferation through direct cell-cell contact. VSIG4 has been implicated in various pathological conditions including cancer, where its expression on tumor-associated macrophages contributes to the immunosuppressive tumor microenvironment, as well as in inflammatory and autoimmune diseases.
The reference antibody patent describes therapeutic applications targeting VSIG4 for modulating immune responses. This biosimilar antibody serves as a valuable research tool for investigating VSIG4-mediated immune regulation, studying macrophage biology, exploring tumor immunity mechanisms, and evaluating potential immunotherapeutic strategies. It enables researchers to examine VSIG4's role in complement regulation and T cell suppression across various experimental models.
There are currently no reviews for this product.